Neogen (NEOG) Aktienübersicht
Die Neogen Corporation entwickelt, produziert und vermarktet verschiedene Produkte und Dienstleistungen für die Lebensmittel- und Tiersicherheit in den Vereinigten Staaten und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 0/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 0/6 |
NEOG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Neogen Corporation Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$9.09 |
| 52-Wochen-Hoch | US$11.43 |
| 52-Wochen-Tief | US$4.53 |
| Beta | 1.97 |
| 1 Monat Veränderung | -3.40% |
| 3 Monate Veränderung | -11.49% |
| 1 Jahr Veränderung | 61.17% |
| 3 Jahre Veränderung | -47.03% |
| 5 Jahre Veränderung | -80.33% |
| Veränderung seit IPO | 3,456.89% |
Aktuelle Nachrichten und Updates
NEOG: Updated 2026 Revenue Outlook Will Support Future Upside Potential
Analysts have nudged their price target on Neogen slightly higher to $12, reflecting updated assumptions around discount rate, profit margin and future P/E that keep fair value broadly in line with prior estimates. What's in the News Neogen updated full fiscal year 2026 guidance, with projected revenue now in a range of $857 million to $860 million.NEOG: Recall Response And Updated 2026 Guidance Will Support Future Upside
Analysts have raised their price target on Neogen from $11.67 to $12.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a higher future P/E of 32.21 compared with 28.61 previously. What's in the News Neogen updated full fiscal year 2026 guidance, indicating expected revenue in a range of $857 million to $860 million, compared with prior guidance of $845 million to $855 million (corporate guidance).Recent updates
NEOG: Updated 2026 Revenue Outlook Will Support Future Upside Potential
Analysts have nudged their price target on Neogen slightly higher to $12, reflecting updated assumptions around discount rate, profit margin and future P/E that keep fair value broadly in line with prior estimates. What's in the News Neogen updated full fiscal year 2026 guidance, with projected revenue now in a range of $857 million to $860 million.NEOG: Recall Response And Updated 2026 Guidance Will Support Future Upside
Analysts have raised their price target on Neogen from $11.67 to $12.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a higher future P/E of 32.21 compared with 28.61 previously. What's in the News Neogen updated full fiscal year 2026 guidance, indicating expected revenue in a range of $857 million to $860 million, compared with prior guidance of $845 million to $855 million (corporate guidance).NEOG: Earnings Outlook Will Benefit From Recall Actions And New Guidance
Analysts have raised their price target on Neogen from $8.17 to $11.67 per share, citing updated assumptions related to the discount rate, revenue growth, profit margins, and a higher future P/E multiple. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials.
NEOG: Recall Resolution Will Shape Bullish View On 2026 Revenue Outlook
Analysts have kept Neogen's price target steady at $13.00, indicating only minor adjustments in assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News Neogen is voluntarily recalling all lots of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials, and is extending the recall to 2 mL / 20 mg vials while its investigation continues (Key Developments).NEOG: 2026 Outlook Will Rely On Recall Resolution For Upside
Analysts are holding Neogen's fair value estimate at $13.00 while modestly adjusting their assumptions around the discount rate, long term revenue trends, profit margins, and future P/E. This reflects updated views on the company’s risk profile and earnings potential without changing the overall price target level.NEOG: 2026 Revenue Outlook Will Support Continued Bullish Thesis
Analysts have maintained Neogen's price target at $13.00, noting that only minor adjustments to assumptions around discount rate, revenue growth, profit margins, and future P/E were made, which do not materially change their valuation view. What's in the News Neogen is voluntarily recalling all lots of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level, after microbial contamination was identified in certain 10 mL/50 mg vials used via intraarticular injection, which is inconsistent with the product's labeled use (Key Developments).Neogen Corporation Could Re-Rate As 3M Food Safety Integration Improves
Feb 16NEOG: Higher Forward P/E And 2026 Outlook Will Support Bullish Thesis
Analysts have raised their price target on Neogen by an implied $3 per share, pointing to adjustments in fair value, discount rate, revenue growth expectations, profit margin assumptions, and a higher forward P/E multiple as the key drivers behind the change. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL/50 mg vials, with an expanded recall to 2 mL/20 mg vials while the investigation continues (Key Developments).Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 46% Jump Looks Justified
Feb 02
NEOG: Future CFO Transition And 2026 Guidance Will Support Measured Outlook
Analysts have raised their fair value estimate for Neogen from US$6.50 to US$10.00, reflecting updated assumptions regarding discount rates, revenue trends, profit margins and a higher future P/E multiple. What's in the News Neogen issued earnings guidance for fiscal 2026, with revenue anticipated in the range of US$845 million to US$855 million, giving investors a sense of management’s current expectations for the business (Key Developments).NEOG: New CFO Appointment Will Support Confidence In Earnings Outlook
Analysts now place a higher implied value on Neogen, lifting their fair value estimate from US$8.00 to US$10.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a richer future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer, effective November 3, 2025.Neogen Corporation (NASDAQ:NEOG) Shares Fly 34% But Investors Aren't Buying For Growth
Dec 19NEOG: Future CFO Transition And Guidance Stability Will Support Measured Outlook
Analysts have raised their price target on Neogen from approximately $5.00 to $6.50 per share, citing a slightly lower discount rate, modestly improved revenue trajectory, better profit margin expectations, and a willingness to assign a higher future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer effective November 3, 2025, with outgoing CFO David Naemura supporting the transition through year end.NEOG: CFO Transition And Alliance Renewal Will Support Future Earnings
Analysts have modestly raised their price target on Neogen by about $0.20 per share, citing a slightly higher assumed discount rate and marginally richer future valuation multiples that together offset minor tweaks to long term growth and margin expectations. What's in the News Reaffirmed fiscal 2026 earnings guidance, maintaining full-year revenue expectations of $820 million to $840 million (company guidance).NEOG: Profit Margin Expansion And CFO Transition Will Drive Earnings Potential
Analysts have raised their price target for Neogen modestly, citing improved profit margin projections and a slightly lower expected future price-to-earnings ratio as key factors behind the adjustment. What's in the News Neogen appointed Bryan Riggsbee as its new Chief Financial Officer, effective November 3, 2025.NEOG: Rising Profit Margins And New Partnerships Will Drive Future Expansion
Narrative Update: Neogen Analyst Price Target Revised Analysts have slightly raised their price target for Neogen, citing improvements in expected profit margins and a modest decline in projected future valuation multiples. This has resulted in a new estimated fair value of $8.17 per share.Food Safety Testing Advances Will Expand Global Opportunities
Neogen's analyst target price has risen from $7.67 to $8.17, as analysts point to improved revenue growth projections alongside a reduced discount rate, both supporting a higher valuation. What's in the News Neogen introduced Molecular Detection Assay: Listeria Right Now, a rapid, enrichment-free tool for detecting Listeria species with results in about two hours and streamlined workflow benefits (Product-Related Announcements).Food Safety Testing Advances Will Expand Global Opportunities
Analysts have raised their price target for Neogen from $6.50 to $7.67, citing a slightly lower discount rate and forward profit expectations. Revenue growth projections remain stable.Is Neogen (NASDAQ:NEOG) Using Too Much Debt?
Jul 10Food Safety And Genomics Will Expand Global Markets
Resilient core businesses, strategic divestitures, and efficiency initiatives are expected to stabilize revenue and expand margins as macro and operational conditions improve.Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 33% Jump Looks Justified
May 16Neogen: A Fair Divestment (Rating Upgrade)
Apr 23Here's Why Neogen (NASDAQ:NEOG) Is Weighed Down By Its Debt Load
Apr 11Neogen: Food Safety Play Is Far From A Safe Pay
Jan 14Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)
Dec 03Does Neogen (NASDAQ:NEOG) Have A Healthy Balance Sheet?
Nov 07Neogen Stock: Expect Volatility To Continue Amid Weak Growth
Oct 11Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)
Aug 28We Think Neogen (NASDAQ:NEOG) Is Taking Some Risk With Its Debt
Jul 31Neogen Corporation: Challenges Remain
Jun 26There's Reason For Concern Over Neogen Corporation's (NASDAQ:NEOG) Price
May 21Battered By M&A Integration Issues, Neogen Has To Rebuild Investor Trust
Apr 15Aktionärsrenditen
| NEOG | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -3.8% | -5.0% | 0.6% |
| 1Y | 61.2% | -19.0% | 28.4% |
Rendite im Vergleich zur Industrie: NEOG übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -19 erzielte.
Rendite vs. Markt: NEOG übertraf den Markt US, der im vergangenen Jahr eine Rendite von 28.4 erzielte.
Preisvolatilität
| NEOG volatility | |
|---|---|
| NEOG Average Weekly Movement | 6.5% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: NEOG hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: NEOGDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1981 | 2,974 | Mike Nassif | www.neogen.com |
Die Neogen Corporation entwickelt, produziert und vermarktet verschiedene Produkte und Dienstleistungen für die Lebensmittel- und Tiersicherheit in den Vereinigten Staaten und international. Das Unternehmen ist in zwei Segmenten tätig: Lebensmittelsicherheit und Tiersicherheit. Das Segment Lebensmittelsicherheit bietet diagnostische Testkits und ergänzende Produkte zum Nachweis gefährlicher und unbeabsichtigter Substanzen in Lebens- und Futtermitteln an, darunter lebensmittelbedingte Krankheitserreger, Verderbniserreger, natürliche Toxine, Lebensmittelallergene, Nebenprodukte von Wiederkäuern, Fleischspeziationen, Arzneimittelrückstände, Pestizidrückstände und allgemeine Hygienemängel sowie Lebensmittelqualität und Nährwertkomponenten.
Neogen Corporation's Grundlagenzusammenfassung
| NEOG grundlegende Statistiken | |
|---|---|
| Marktanteil | US$2.07b |
| Gewinn(TTM) | -US$608.84m |
| Umsatz(TTM) | US$870.56m |
2.3x
Kurs-Umsatz-Verhältnis-3.2x
Kurs-Gewinn-Verhältnis Ist NEOG zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| NEOG Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$870.56m |
| Kosten der Einnahmen | US$476.99m |
| Bruttogewinn | US$393.58m |
| Sonstige Ausgaben | US$1.00b |
| Gewinn | -US$608.84m |
Zuletzt gemeldete Gewinne
Feb 28, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -2.80 |
| Bruttomarge | 45.21% |
| Nettogewinnspanne | -69.94% |
| Schulden/Eigenkapital-Verhältnis | 37.8% |
Wie hat sich NEOG auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/04 03:49 |
| Aktienkurs zum Tagesende | 2026/05/04 00:00 |
| Gewinne | 2026/02/28 |
| Jährliche Einnahmen | 2025/05/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Neogen Corporation wird von 16 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Robert Labick | CJS Securities, Inc. |
| David Westenberg | CL King & Associates, Inc. |